Abiopharma

Volition Signs First Human Out Licensing Deal

New Form DEFA14A - INTENSITY THERAPEUTICS, INC. Filed: 2025-09-09 AccNo: 0001567264-25-000091 Size: 1 MB

New Form DEF 14A - INTENSITY THERAPEUTICS, INC. Filed: 2025-09-09 AccNo: 0001567264-25-000090 Size: 1 MB

New Form 8-K/A - Strawberry Fields REIT, Inc. Filed: 2025-09-09 AccNo: 0001493152-25-012849 Size: 381 KB Item 9.01: Financial Statements and Exhibits

Citius Oncology - Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

CyncHealth Nebraska Expands Partnership with Health Catalyst to Accelerate Measurable Improvement in Nebraska

Teva Pharmaceutical Industries Ltd. - Teva’sEmrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

New Form 6-K - Tiziana Life Sciences Ltd Filed: 2025-09-09 AccNo: 0001213900-25-085865 Size: 29 KB

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton

REMINDER: Microbot Medical to Highlight FDA 510(k) Clearance of the LIBERTY Endovascular Robotic System at the H.C. Wainwright Annual Investor Conference